Drug Profile
Lorazepam intranasal - Amarin
Alternative Names: AMR-108; Nasal lorazepamLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Elan Corporation
- Developer Amarin Corporation
- Class Antiemetics; Anxiolytics; Benzodiazepinones; Hypnosedatives; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Seizures; Status epilepticus
Most Recent Events
- 25 Sep 2008 Lorazepam intranasal is available for licensing (http://www.amarincorp.com)
- 14 Jan 2008 Amarin Corporation completes a preclinical, proof-of-concept trial in Seizures and Status epilepticus
- 06 Mar 2007 Lorazepam intranasal licensed to Amarin Corporation worldwide